Treatment of Chronic Leg Ulcers With Autologous Stromal Vascular Fraction

December 6, 2016 updated by: Navid Toyserkani, Odense University Hospital
Chronic leg ulcers are associated with decreased quality of life and an increased mortality. In many cases these ulcers are treated conservatively and the healing time can be several months. In this open randomized clinical trial we will examine if we can accelerate wound healing when using autologous stromal vascular fraction as an adjunct to standard wound care.

Study Overview

Detailed Description

Chronic leg ulcers are associated with decreased quality of life and an increased mortality. In many cases these ulcers are treated conservatively and the healing time can be several months. In this open randomized clinical trial we will examine if we can accelerate wound healing when using autologous stromal vascular fraction (SVF) as an adjunct to standard wound care.

The plan is to include 30 patients with arterial or arteriovenous chronic leg ulcers and these are randomized in two groups of which one receives standard wound care only and the other group receives autologous stromal vascular fraction treatment in addition to standard wound care.

Study Type

Interventional

Enrollment (Anticipated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Odense, Denmark, 5000
        • Recruiting
        • Odense University Hospital
        • Contact:
        • Principal Investigator:
          • Navid M Toyserkani, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Arteriovenous chronic leg ulcer
  • Present beyond 4 months
  • Conservative treatment not leading to progress
  • Wound size between 2-30cm2
  • ankle-brachial index (ABI) ( 50-90% and/or toe pressure 50-70% and where ankle pressure > 60 mmHg or toe pressure > 40 mmHg
  • Written informed consent

Exclusion Criteria:

  • Uncontrolled wound infection
  • Osteomyelitis
  • Hemoglobin <6.0mmol/L
  • HbA1c >80mmol/mol
  • Underlying malignancy
  • Pregnancy or lactating
  • Renal insufficiency requiring dialysis
  • Charcot foot
  • Underlying malignancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Autologous SVF + Standard of care

local injection around and under wound with autologous stromal vascular fraction.

Standard wound care is given independent of this study.

Adipose tissue is harvested by liposuction from either abdomen or thighs.
Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.
Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
OTHER: Standard of care
Standard wound care is given independent of this study.
Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in wound size
Time Frame: 6 months
Photography is taken every 2 weeks until complete wound healing. Final follow-up date regardless of complete wound healing or not is 6 months.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Distal blood pressure measurement
Time Frame: 6 months
Change in distal blood pressure measurement before and 6 months after treatment
6 months
Transcutaneous oxygen tension
Time Frame: 6 months
Change in transcutaneous oxygen tension around the wound before and 6 months after treatment.
6 months
Treatment-related adverse events
Time Frame: 6 months
Monitoring of any side effects or complications related to intervention
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Jens A Sørensen, MD PhD, Dept. Plastic Surgery, OUH, Consultant, Professor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2016

Primary Completion (ANTICIPATED)

June 1, 2018

Study Completion (ANTICIPATED)

June 1, 2018

Study Registration Dates

First Submitted

November 24, 2016

First Submitted That Met QC Criteria

December 6, 2016

First Posted (ESTIMATE)

December 8, 2016

Study Record Updates

Last Update Posted (ESTIMATE)

December 8, 2016

Last Update Submitted That Met QC Criteria

December 6, 2016

Last Verified

December 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • S-201502002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Leg Ulcer

Clinical Trials on Liposuction

3
Subscribe